Binet Staging System for Chronic Lymphocytic Leukemia (CLL)

ورودی‌های بالینی بیمار

حداقل ۳ — حداکثر ۲۰ • واحد: g/dL

حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10³/mm³

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
binet stage
—stage
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Stage A1–1
  • Stage B2–2
  • Stage C3–3
Direct Clinical Answer

The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include cervical lymphadenopathy. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions

Clinical Indication

The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) is indicated for bedside clinical practice to support Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Treatment decisions should incorporate clinical symptoms, performance status, and comorbidities.

Formula & Variables:

Count lymphoid areas involved (cervical, axillary, inguinal, spleen, liver). Stage A: <3 areas + normal Hgb/platelets. Stage B: ≥3 areas + normal Hgb/platelets. Stage C: Anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelets <100×10³/mm³)

Input Parameters

NameTypeRequiredDescription
cervical_lymphadenopathystringYesEnlarged cervical lymph nodes (neck region)
axillary_lymphadenopathystringYesEnlarged axillary lymph nodes (underarm region)
inguinal_lymphadenopathystringYesEnlarged inguinal lymph nodes (groin region)
splenomegalystringYesEnlarged spleen (splenomegaly)
hepatomegalystringYesEnlarged liver (hepatomegaly)
hemoglobinfloatYesHemoglobin level in g/dL(g/dL)
platelet_countintegerYesPlatelet count in thousands per mm³ (×10³/mm³)(×10³/mm³)

Score Interpretation & Guidance

RangeStageDescription
1–1Stage ALow risk - <3 lymphoid areas involved, normal Hgb and platelets
2–2Stage BIntermediate risk - ≥3 lymphoid areas involved, normal Hgb and platelets
3–3Stage CHigh risk - Anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelets <100×10³/mm³)

Evidence-Based References (EBM)

  • Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206.
  • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760.
  • Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34.

Related calculators